Get the Stockscreener App
4.04
1.51%
0.06
Astria Therapeutics Inc stock is traded at $4.04, with a volume of 202.27K.
It is up +1.51% in the last 24 hours and down -37.65% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$3.98
Open:
$3.97
24h Volume:
202.27K
Relative Volume:
0.69
Market Cap:
$238.15M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-1.6694
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
-0.49%
1M Performance:
-37.65%
6M Performance:
-65.65%
1Y Performance:
-61.71%
1-Day Range:
$3.925
$4.1764
1-Week Range:
$3.925
$4.39
52-Week Range:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
4.04 | 238.15M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Vanguard Group Inc. - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Raymond James Financial Inc. Takes $707,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Long Term Trading Analysis for (ATXS) - news.stocktradersdaily.com
Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Astria Therapeutics Grants $235K Worth of Stock Options to Strategic New Hires - Stock Titan
Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $26.60 - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Investment Report - news.stocktradersdaily.com
What is Lifesci Capital’s Forecast for ATXS FY2025 Earnings? - The AM Reporter
Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for ATXS Q1 Earnings? - Defense World
Q1 EPS Forecast for Astria Therapeutics Decreased by Analyst - Defense World
Astria Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
(ATXS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Astria Therapeutics price target raised to $28 from $27 at Wedbush - TipRanks
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating - Marketscreener.com
Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World
Astria Therapeutics Advances Clinical Trials and Financials - TipRanks
Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks
Astria Therapeutics, Inc. SEC 10-K Report - TradingView
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating - TipRanks
Preclinical data reported for Astria’s anti-OX40 monoclonal antibody - BioWorld Online
Astria Therapeutics posts marginally smaller-than-expected quarterly net loss per share - Marketscreener.com
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by New York State Common Retirement Fund - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.67 - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Astria Therapeutics Issues 87,450 Stock Options: What This Means for Shareholder Dilution - Stock Titan
Learn to Evaluate (ATXS) using the Charts - news.stocktradersdaily.com
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (ATXS) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Press Release From Business Wire: Astria Therapeutics, Inc. - UrduPoint News
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Business Wire
Can Astria's Navenibart Change the Game for HAE Patients? Phase 3 Trial Begins After 95% Attack Reduction - Stock Titan
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Business Wire
Can Astria Therapeutics' Conference Appearance Signal New Developments in Allergic Disease Treatments? - Stock Titan
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
When the Price of (ATXS) Talks, People Listen - Stock Traders Daily
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire
Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next? - Defense World
Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts - Defense World
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):